How Due Diligence Facilitates Successful Biotech Investments, Deals, and Partnerships
Emerging companies constitute about 90% of the total biopharmaceutical market by number of companies comprising 70% of the global clinical pipeline. Few of these companies have the experience or expertise to transition biopharmaceuticals from research through to approval. Furthermore, they generally lack the financial capital required to fund through to product approval. For these companies to be successful, they need to secure a combination of sophisticated investors, partners, and expert consultants with a track record of success in helping bring new, cost-effective therapies to market.
This webinar will provide insights that could immediately be used in your development programs and could improve your readiness for deal and investment engagements.
Speaker(s): Fran Brown, Certara
Date: Tuesday, March 5, 2019
Time: 11:00 am EST
Duration: 1 hour